SutroVax picks up $85 million in Series C round for pneumococcal vaccine
SutroVax, spun off from Sutro Biopharma, also announced a contract manufacturing deal with Swiss vendor Lonza.
SutroVax nets $22M Series A for conjugate vaccine work
Bay Area startup SutroVax just raised $22 million for work in developing conjugate vaccines - and likely improving upon existing inoculations for pneumococcal conditions.
presented by
The Top 6 Best Analytics Tools for Health Care Revenue in 2025
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.